Free tool
FAERS Monitor: Roxicodone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021011 or its brand name (Roxicodone, Oxycodone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
92,014
Serious
81,137
88% of reports
Hospitalization
16,660
Death reported
32,198
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug dependence27,118
- pain19,074
- overdose17,568
- emotional distress15,366
- death14,251
- toxicity to various agents12,632
- drug withdrawal syndrome10,112
- fatigue4,126
- drug ineffective4,075
- drug abuse3,739
- nausea3,739
- anxiety2,931
- off label use2,914
- dyspnoea2,836
- rash2,727
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 60 |
| 2006 | 104 |
| 2007 | 108 |
| 2008 | 181 |
| 2009 | 160 |
| 2010 | 263 |
| 2011 | 272 |
| 2012 | 603 |
| 2013 | 865 |
| 2014 | 771 |
| 2015 | 1,070 |
| 2016 | 2,492 |
| 2017 | 4,304 |
| 2018 | 25,281 |
| 2019 | 3,325 |
| 2020 | 5,469 |
| 2021 | 14,161 |
| 2022 | 15,910 |
| 2023 | 4,654 |
| 2024 | 4,197 |
| 2025 | 4,453 |
| 2026 | 3,265 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,962,145 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug dependenceSignal | 27,118 | 46.2 | 45.6 | 1,003,901 |
| emotional distressSignal | 15,366 | 33.1 | 32.6 | 419,816 |
| drug withdrawal syndromeSignal | 10,112 | 29.6 | 29.1 | 248,627 |
| overdoseSignal | 17,568 | 20.2 | 19.9 | 297,176 |
| toxicity to various agentsSignal | 12,632 | 18.4 | 18.1 | 194,144 |
| drug abuseSignal | 3,739 | 10.7 | 10.4 | 31,529 |
| painSignal | 19,074 | 7.3 | 7.2 | 103,375 |
| deathSignal | 14,251 | 3.8 | 3.8 | 30,528 |
| anxietySignal | 2,931 | 2.4 | 2.3 | 2,323 |
| rash | 2,727 | 1.4 | 1.4 | 361 |
| fatigue | 4,126 | 1.2 | 1.2 | 159 |
| dyspnoea | 2,836 | 1.1 | 1.1 | 54 |
| nausea | 3,739 | 1.1 | 1.0 | 23 |
| off label use | 2,914 | 0.8 | 0.7 | 230 |
| drug ineffective | 4,075 | 0.7 | 0.7 | 531 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.